MedTrace Logo

Safety and Tolerability Study of MBX-2044 in Patients With Type 2 Diabetes

NCT00422487 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2015-05-01

No results posted yet for this study

Summary

The purpose of this study is to collect important information regarding the glucose-lowering efficacy of MBX-2044 and the safety of MBX-2044 (especially weight gain and edema) in diabetics. It will also provide important information about the appropriate doses to be used in subsequent longer-term studies to evaluate the safety and efficacy of MBX-2044 alone and in combination with other anti-diabetic agents.

Conditions

Interventions

DRUG

MBX-2044

MBX-2044 1.5 mg one capsule daily for 14 days

DRUG

MBX-2044

MBX-2044 4.5 mg three 1.5 mg capsules daily for 14 days

DRUG

MBX-2044

MBX-2044 15 mg one capsule daily for 14 days

DRUG

MBX-2044

MBX-2044 30 mg two 15 mg capsules daily for 14 days

DRUG

MBX-2044

MBX-2044 60 mg one capsule daily for 14 days

DRUG

MBX-2044

MBX-2044 90 mg one 60 mg capsule and two 15 mg capsules daily for 14 days

DRUG

Placebo for MBX-2044

Placebo Intervention

Sponsors & Collaborators

Principal Investigators

  • Sherwyn Schwartz, MD · Diabetes and Glandular Research Associates

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2007-08-31
Completion
2007-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00422487 on ClinicalTrials.gov